Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.49 |
| ▸ | MMP2 | P08253 | 3/20 | 0.48 |
| ▸ | MMP9 | P14780 | 3/20 | 0.48 |
| ▸ | MMP8 | P22894 | 3/20 | 0.48 |
| ▸ | MMP13 | P45452 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.46 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.46 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.45 |
| ▸ | NPBWR1 | P48145 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30917347 | 0.87 | CYP19A1 (0.60) | ALDH1A1POLBCYP19A1MAPTLMNA | |
| SCHEMBL317330 | 0.87 | CYP19A1 (0.60) | ALDH1A1POLBCYP19A1MAPTLMNA | |
| SCHEMBL1082243 | 0.78 | CA12 (0.47) | ALDH1A1POLBCYP19A1MMP2MMP9 | |
| SCHEMBL1630724 | 0.77 | MAPT (0.51) | ALDH1A1POLBMMP2MMP9MMP8 | |
| SCHEMBL5738096 | 0.76 | MMP13 (0.69) | ALDH1A1MMP2MMP13MAPTLMNA | |
| SCHEMBL5797966 | 0.76 | PTGS2 (0.60) | ALDH1A1PTGS2CYP19A1MAPTLMNA | |
| SCHEMBL7518475 | 0.76 | CYP19A1 (0.65) | ALDH1A1POLBCYP19A1MMP2MMP9 | |
| SCHEMBL10122036 | 0.75 | CYP2A6 (0.72) | ALDH1A1PTGS2MAPTLMNAHPGD | |
| SCHEMBL27765605 | 0.75 | PTGS2 (0.59) | ALDH1A1PTGS2MAPTMEN1KMT2A | |
| SCHEMBL28534328 | 0.75 | ALDH1A1 (0.47) | ALDH1A1POLBCYP19A1MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2412706-B1 | NOVEL HYDROXAMATE DERIVATIVE, A PRODUCTION METHOD FOR THE SAME, AND A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARM CORP (KR) | 2014-10-29 | — | — | EP | disclosed |
| US-8466161-B2 | Hydroxamate derivative, a production method for the same, and a pharmaceutical composition comprising the same | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2013-06-18 | — | — | US | disclosed |
| US-20120028963-A1 | NOVEL HYDROXAMATE DERIVATIVE, A PRODUCTION METHOD FOR THE SAME, AND A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2012-02-02 | — | — | US | disclosed |
| EP-2412706-A2 | NOVEL HYDROXAMATE DERIVATIVE, A PRODUCTION METHOD FOR THE SAME, AND A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Chong Kun Dang Pharmaceutical Corp. (KR) | 2012-02-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028963-A1 | NOVEL HYDROXAMATE DERIVATIVE, A PRODUCTION METHOD FOR THE SAME, AND A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HAAO, HPD, HCAR2 | ALDH1A1 910/4885POLB 1921/4885PTGS2 433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.